NCT01712490 · OUTCOME

A+AVD: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Brentuximab Vedotin ADC and TAb

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma · Source last updated 2026-02-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: day*microgram per milliliter (day*ug/mL)
Interval / dispersion: Standard Deviation
Time frame: Cycle 1 Day 1: pre-dose and at multiple timepoints (up to 48 hours) post-dose

Analysis population: The PK population included enrolled participants with sufficient dosing and PK data to reliably estimate PK parameters as determined by a clinical pharmacologist. The iPK population was the subset of PK population. The iPK population where data at specified timepoints was available.

Groups in this outcome

A+AVD

Brentuximab vedotin 1.2 milligram per kilogram (mg/kg), infusion, intravenously over 30-minutes plus doxorubicin 25 milligram per square meter (mg/m\^2), vinblastine 6 mg/m\^2, and dacarbazine 375 mg/m\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles. Brentuximab vedotin was administered within approximately 1 hour after completion of AVD.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
A+AVD	59

Reported measurements

Cycle 1 Day 1: ADC

Analysis denominator · Participants

Group	Source count
A+AVD	53

Values in day*microgram per milliliter (day*ug/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
A+AVD	47.4	12.0	Not reported	Not reported	Not reported

Cycle 1 Day 1: TAb

Analysis denominator · Participants

Group	Source count
A+AVD	51

Values in day*microgram per milliliter (day*ug/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
A+AVD	93.0	25.7	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
spread
12.0
value
47.4
denoms
counts
group Id
OG000
value
53
units
Participants
title
Cycle 1 Day 1: ADC
categories
measurements
group Id
OG000
spread
25.7
value
93.0
denoms
counts
group Id
OG000
value
51
units
Participants
title
Cycle 1 Day 1: TAb

denoms

counts
group Id
OG000
value
59
units
Participants

dispersion Type

Standard Deviation

groups

description
Brentuximab vedotin 1.2 milligram per kilogram (mg/kg), infusion, intravenously over 30-minutes plus doxorubicin 25 milligram per square meter (mg/m\^2), vinblastine 6 mg/m\^2, and dacarbazine 375 mg/m\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles. Brentuximab vedotin was administered within approximately 1 hour after completion of AVD.
id
OG000
title
A+AVD

param Type

MEAN

population Description

The PK population included enrolled participants with sufficient dosing and PK data to reliably estimate PK parameters as determined by a clinical pharmacologist. The iPK population was the subset of PK population. The iPK population where data at specified timepoints was available.

reporting Status

POSTED

time Frame

Cycle 1 Day 1: pre-dose and at multiple timepoints (up to 48 hours) post-dose

title

A+AVD: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Brentuximab Vedotin ADC and TAb

type

SECONDARY

unit Of Measure

day*microgram per milliliter (day*ug/mL)

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice